<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145376</url>
  </required_header>
  <id_info>
    <org_study_id>TaMi01</org_study_id>
    <nct_id>NCT03145376</nct_id>
  </id_info>
  <brief_title>Clinical and Geriatric Assessment in Elderly Patients Before and After TAVI or MitraClip Positioning</brief_title>
  <official_title>Clinical Evaluation and Geriatric Assessment in Elderly Patients Before and After Percutaneous Aortic Valve Implantation (TAVI) or MitraClip Positioning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since October of 2014, the Policlinico Umberto I Hospital has an &quot;Heart Team&quot;, a group of&#xD;
      selected specialists with the task of assessing and identifying eligible patients for&#xD;
      valvular aortic transcatheter implantation (TAVI) or a placement of a MitraClip .&#xD;
&#xD;
      The specialists taking part to Heart Team are: a cardiologist, a heart surgeon, a vascular&#xD;
      surgeon, an anesthesiologist and a geriatrician.&#xD;
&#xD;
      The Geriatrician is called to make a careful multidimensional assessment of the elderly&#xD;
      patients who have been suggested for the interventions mentioned above. His role is to assess&#xD;
      the degree of co-morbidity and polypathology, autonomy in the common activities of daily&#xD;
      living, nutritional status, cognitive status and quality of life. Following this evaluation,&#xD;
      together with the other components of Heart Team, it is expressed a collective judgment on&#xD;
      the patient's eligibility to these interventions. So, the aim of the present study is to&#xD;
      identify changes in the degree of cognitive decline, of autonomy in carrying out activities&#xD;
      of daily living, quality of life, nutritional status, pre- and postoperatively (6 months&#xD;
      after the procedure) polypathology degree in elderly patients to be undergone or undergoing&#xD;
      TAVI or positioning MitraClip because suffering from aortic valvular stenosis or severe&#xD;
      mitral insufficiency. The patients undergo to a battery of tests, to a 5 minutes&#xD;
      electrocardiographic record to evaluate the Heart Rate Variability (HRV) and to a complete&#xD;
      echocardiographic evaluation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortic stenosis (AS) is a progressive chronic valvular disease that progressively and rapidly&#xD;
      leads to the development of heart failure. This pathology, which is typical of the elderly,&#xD;
      is increasing together with the age of the population and it is a candidate for the&#xD;
      development of less invasive and innovative therapies that enable the treatment of older&#xD;
      patients with polypathology and high degree of comorbidity. According to the most recent&#xD;
      guidelines for the treatment of valvular heart disease, the degenerative AS is the most&#xD;
      common valve disease in Western countries especially in the group aged over 65 years. The&#xD;
      degenerative AS, in its most severe form, is a highly debilitating chronic condition&#xD;
      characterized by symptoms as such precordial pain suggestive of angina, transient altered&#xD;
      state of consciousness, or syncope, dyspnea and other heart failure symptoms secondary to&#xD;
      reduced stroke volume. A recent systematic review (2) estimated the prevalence of AS in the&#xD;
      elderly population aged over 75 years amounted to 12.4% while the prevalence of severe AS&#xD;
      amounted to 3.4%. The average survival after the onset of symptoms is about 2-3 years. The&#xD;
      natural history of the disease is not modified by conservative treatment and, to date, the&#xD;
      surgical aortic valve replacement is recommended by both the American and European guidelines&#xD;
      for patients with severe symptomatic and asymptomatic patients with reduced ejection fraction&#xD;
      (80 years obtain appreciable results with a less than 10% mortality and morbidity between 5&#xD;
      and 10%. Some conditions, such as the presence of comorbidities (chronic obstructive&#xD;
      pulmonary disease, vasculopathy, chronic renal failure, dementia and other) and the advanced&#xD;
      age of the patients, make the surgery too risky or impossible to achieve. Therefore,&#xD;
      approximately one third of patients in advanced age is not currently subjected to surgery.&#xD;
&#xD;
      After the &quot;first man&quot; made in 2002, TAVI has been introduced in the clinic in 2007 and has&#xD;
      quickly gained critical acclaim. Up to now, about 150,000 TAVI procedures were performed with&#xD;
      a growing trend.&#xD;
&#xD;
      The methodical approach of the techniques involve various approaches: transfemoral,&#xD;
      transapical, (the two most popular), transaxillary, transaortic.&#xD;
&#xD;
      The enormous diffusion of the method follows the growing demand. Conservative treatment of&#xD;
      the SA guarantees any improvement; optimized drugs therapy is able nor to mitigate the&#xD;
      symptomatology associated nor to resolve the underlying disease.&#xD;
&#xD;
      The surgery requires the use of extracorporeal circulation and, although conducted in the&#xD;
      less invasive way possible, it remains an intervention in which elderly patients with&#xD;
      polypathology and high degree of comorbidity are hardly addressed.&#xD;
&#xD;
      A clinical evaluation and multidimensional geriatric assessment are indispensable to ensure a&#xD;
      correct diagnosis of the patient, estimating the risk of periprocedural mortality and&#xD;
      morbidity and evaluate the actual possibility of intervention benefit on the patient's&#xD;
      overall health.&#xD;
&#xD;
      MitraClip&#xD;
&#xD;
      The severe mitral regurgitation is a clear indication to intervention of mitral repair which&#xD;
      has advantages compared to traditional surgery, preserving the contractile function of the&#xD;
      left ventricle, reducing the incidence of adverse events related to the system of the&#xD;
      prosthesis, by reducing the hospital mortality, morbidity and hospitalization, improving the&#xD;
      long-term survival. The surgical risk of mitral plastic surgery presents a percentage lower&#xD;
      than 2.5% in the centers that perform no less than 140 operations per year. However, an&#xD;
      ejection fraction (FE) of the left ventricle lower than 55% is a negative prognostic index.&#xD;
      In addition, the mitral plastic surgery has a long and difficult learning curves, but also&#xD;
      the indisputable advantage of less invasiveness than traditional surgery, which allows its&#xD;
      use even in patients deemed to be at higher operative risk. The placement of a MitraClip is&#xD;
      the evolution of conventional surgery (Alfieri's speech): percutaneous, trans-septal&#xD;
      puncture, placing clips on the mitral leaflets to create a dual orifice and therefore&#xD;
      decrease or completely abolish the valve insufficiency . The EVEREST II study has shown that&#xD;
      this procedure is less effective than surgery in reducing the degree of mitral regurgitation,&#xD;
      but the percutaneous repair of mitral regurgitation is more secure and has shown improved&#xD;
      clinical outcomes, comparable to cardiac surgery. At a post-hoc analysis, patients who&#xD;
      benefit most from the MitraClip patients are elderly with low ejection fraction and&#xD;
      functional mitral insufficiency. Considering that the prevalence of mitral insufficiency in&#xD;
      the elderly is 30-50%, it is comprehensible how the MitraClip will have certain evolution in&#xD;
      numerical terms.&#xD;
&#xD;
      The MitraClip is, therefore, a valid therapeutic option in case of functional mitral&#xD;
      regurgitation, since the surgery in these patients is burdened with high mortality, by high&#xD;
      recurrence of mitral regurgitation and a long hospital stay.&#xD;
&#xD;
      The MitraClip is to be used in a small number of properly selected patients. The procedural&#xD;
      success depends on the ability to choose an individualized therapy for each patient depending&#xD;
      on valvular anatomy, valve functionality, on comorbidities and on patient's life expectation,&#xD;
      performing an estimation of the risk-benefit of the two percutaneous techniques and surgical&#xD;
      intervention.&#xD;
&#xD;
      This estimate and evaluation of the patient must be operated in the geriatric&#xD;
      multidisciplinary field, to ensure a comprehensive risk assessment of patients and their best&#xD;
      selection.&#xD;
&#xD;
      Aim of the study&#xD;
&#xD;
      Identify changes in the degree of cognitive decline, of autonomy in carrying out activities&#xD;
      of daily living, quality of life, nutritional status, pre- and postoperatively (6 months&#xD;
      after the procedure) polypathology degree in elderly patients to be undergone or undergoing&#xD;
      TAVI or positioning MitraClip because suffering from aortic valvular stenosis or severe&#xD;
      mitral insufficiency. The patients undergo to a battery of tests, to a 5 minutes&#xD;
      electrocardiographic record to evaluate the Heart Rate Variability (HRV) and to a complete&#xD;
      echocardiographic evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in cognitive impairment evaluation using minimental state examination (MMSE)</measure>
    <time_frame>Baseline evaluation and a new one after 6 months to evaluate possible changes</time_frame>
    <description>evaluation of the pre and post-operative cognitive impairment using the same test (mini mental state examination, MMSE: tot 28-30 points no cognitive impairment, 24-27 borderline, 19-23 mild cognitive impairment, 14-18 moderate cognitive impairment, &lt;14 severe cognitive impairment)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline evaluation and a new one after 6 months</time_frame>
    <description>evaluation of the pre- and post-operative patient's quality of life with SF36 scale: 2 cumulative scores for physical and mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>polypathology status evaluation with CIRS scale</measure>
    <time_frame>Baseline evaluation and a new one after 6 months</time_frame>
    <description>Cumulative Illness Rating Scale: ICS and ICC, cumulative final score can vary theoretically vary from 0 to 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADL: Activities of Daily Living</measure>
    <time_frame>Baseline evaluation and a new one after 6 months</time_frame>
    <description>Rating capability to attend 6 Activities of Daily Living (Have shower; Dressing; Going to the toilet; urinary incontinence; walking; having meal: tot score 0-6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IADL:InstrumentalActivities of Daily Living</measure>
    <time_frame>Baseline evaluation and a new one after 6 months</time_frame>
    <description>rating capability to perform Instrumental Activities of Daily Living: using phone, shopping food, using means of transport, taking therapy, money management (for male and female) and doing laundry, doing housework and preparing meal evaluated just for female.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MNA:Mini Nutritional Assessment</measure>
    <time_frame>Baseline evaluation and a new one after 6 months</time_frame>
    <description>Evaluation of nutritional status with mini nutritional assessment score: max 30 points (optimal nutritional status)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>phone call after 6 months from baseline evaluation</time_frame>
    <description>time death after procedure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Aortic Stenosis Senile</condition>
  <arm_group>
    <arm_group_label>patients before and after TAVI/MitraClip</arm_group_label>
    <description>geriatric assessment of patients before and after TAVI/Mitraclip</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>geriatric assessment</intervention_name>
    <description>Clinical evaluation and geriatric assessment with:&#xD;
CIRS: CIRS (Cumulative Illness Rating Scale)&#xD;
ADL (Activities of Daily Living);&#xD;
IADL (InstrumentalActivities of Daily Living);&#xD;
Mini Nutritional Assessment;&#xD;
Evaluation of quality of life (Short Form 36, SF-36).&#xD;
Making a traditional 12-lead ECG.&#xD;
A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;&#xD;
transthoracic echocardiogram.</description>
    <arm_group_label>patients before and after TAVI/MitraClip</arm_group_label>
    <other_name>ECG</other_name>
    <other_name>Heart Rate Variability</other_name>
    <other_name>Echocardiogram</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        elderly patients with severe aortic stenosis eligible for TAVI or affected by mitral valve&#xD;
        severe insufficiency treatable by MitraClip positioning.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age higher than or equal to 65 aa;&#xD;
&#xD;
          -  the capacity to perform geriatric assessment tests;&#xD;
&#xD;
          -  sinus rhythm at the time of evaluation (for the evaluation of HRV only);&#xD;
&#xD;
          -  to sign appropriate informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  altered cognitive abilities such as to impair the evaluation;&#xD;
&#xD;
          -  hemodynamically unstable patient;&#xD;
&#xD;
          -  Inability or unwillingness to sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianfranco Piccirillo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapienza</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gianfranco Piccirillo, MD, PhD</last_name>
    <phone>+393356759046</phone>
    <email>gianfranco.piccirillo@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Federica Moscucci, MD</last_name>
    <phone>+393403304642</phone>
    <email>federica.moscucci@uniroma1.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gianfranco Piccirillo</name>
      <address>
        <city>Rome</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federica Moscucci, MD</last_name>
      <email>federica.moscucci@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>FEDERICA MOSCUCCI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>FABIOLA MASTROPIETRI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CLAUDIA DI IORIO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ILARIA PARROTTA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>GAETANA MARIA GRAZIA STRICCHIOLA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARCELLA FABIETTI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>DAMIANO MAGRÃ¬, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MAURO CACCIAFESTA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Moscucci, MD</last_name>
      <phone>+393403304642</phone>
      <email>federica.moscucci@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>GIANFRANCO PICCIRILLO, MD, PhD</last_name>
      <phone>+390649972349</phone>
      <email>gianfranco.piccirillo@uniroma1.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>March 27, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Gianfranco Piccirillo</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>MitraClip</keyword>
  <keyword>geriatric assessment</keyword>
  <keyword>heart rate variability</keyword>
  <keyword>elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

